Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202747 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
A Phase 2 study, sponsored by TearScience.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01202747 is a Phase 2 study that has completed, run by TearScience. The registered enrollment target is 50 participants.
The verdict
NCT01202747, a Phase 2 study, has completed, sponsored by TearScience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye, and chalazia. The screening methods include diagnostic expression of the meibomian glands and interferometry assessment of the tear film.
Interventions
- DEVICE LipiFlow System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202747
The ClinicalTrials.gov registry entry for NCT01202747 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TearScience, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LipiFlow System is the first listed.
NCT01202747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202747 about?
NCT01202747 is a clinical study titled "Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction". The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also kno...
What is the current status of trial NCT01202747?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-09. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01202747?
The interventions under investigation include: LipiFlow System (DEVICE).
Who is sponsoring clinical trial NCT01202747?
This trial is sponsored by TearScience, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.